The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A.

@article{Lusher2003TheSA,
  title={The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A.},
  author={J. Lusher and Christine A. Lee and Craig Kessler and Camille L. Bedrosian},
  journal={Haemophilia : the official journal of the World Federation of Hemophilia},
  year={2003},
  volume={9 1},
  pages={
          38-49
        }
}
BACKGROUND B-domain-deleted recombinant factor VIII (BDDrFVIII) was developed when the B-domain was found to be redundant for maintaining haemostasis. This allows formulation of the final product without albumin added as a stabilizer. METHODS Three multicentre clinical studies and one pharmacokinetic study were conducted in 218 patients to evaluate the safety and haemostatic efficacy of BDDrFVIII. RESULTS Previously treated patients (n = 113; median duration, 1711 days; median exposure days… CONTINUE READING

From This Paper

Topics from this paper.
48 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 48 extracted citations

Similar Papers

Loading similar papers…